Inhalation Sciences receives IRS order worth 35,000 Euro from global generics company
Inhalation Sciences AB (ISAB) has received an order from a new client, a global generics company, for an Inhalation Research Services (IRS) project. The client has chosen ISAB’s DissolvIt[®] for the project, due to its outstanding accuracy in testing generic formulations against originator products to define bioequivalence and, potentially, IVIVC (In Vitro In Vivo correlation), both critical metrics in generic drug development.The new client’s development team are highly expert and experienced in Pharmacokinetics (PK), bioequivalence and dissolution studies. They have chosen ISAB’s